Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
1.
Biol Res Nurs ; 26(2): 231-239, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-37844913

RESUMO

Obesity is highly prevalent in breast cancer (BC) survivors. Adipose tissue promotes inflammation, affecting recurrence, morbidity, and quality of life. This study aimed to determine the relationship of body composition parameters with the levels of C-reactive protein (CRP) and interleukin 6 (IL-6) in female BC survivors. Additionally, we evaluated the association of log-transformed serum concentrations of CRP and IL-6 with the appendicular skeletal lean mass index (ASMI). The results showed that CRP was positively associated with body fat percentage (BFP; ß adjusted = .08, 95% CI: .02-.14) in all participants, and with fat mass index (FMI; ß = .24, 95% CI: .08-.40) only in premenopausal women. IL-6 was positively associated with FMI (ß adjusted = .16, 95% CI: .03-.29), while ASMI decreased as CRP levels increased (ß adjusted = -.30, 95% CI: -.53 to -.06). Interventions to improve body composition in BC survivors should also consider the role of inflammatory markers in changes in body composition to avoid sarcopenic obesity (SO) and the risk of BC recurrence.


Assuntos
Neoplasias da Mama , Sobreviventes de Câncer , Humanos , Feminino , Interleucina-6 , Proteína C-Reativa , Neoplasias da Mama/complicações , Qualidade de Vida , Recidiva Local de Neoplasia/complicações , Composição Corporal , Obesidade/complicações , Sobreviventes , Índice de Massa Corporal
2.
Ann Surg ; 2023 Oct 23.
Artigo em Inglês | MEDLINE | ID: mdl-37870257

RESUMO

OBJECTIVE: To analyze the impact of Body Mass Index (BMI) on clinical and patient-reported outcomes following gender-affirming mastectomy (GM). BACKGROUND: BMI is a barrier for obese patients seeking GM despite increasing evidence that it is safe in this population. Currently little is known about the impact of BMI on chest-specific body image and satisfaction following GM. METHODS: This single-center, cross-sectional study included individuals 18 years and older who underwent GM between 1990-2020 and were at least 2 years post-operative. Patient-reported chest-specific body image was measured using the BODY-Q and Gender Congruence and Life Satisfaction (GCLS) chest subscales. Satisfaction was measured using the Holmes-Rovner Satisfaction with Decision (SWD) scale. Clinical and demographic variables were identified from chart review. Bivariate analysis was performed to determine if BMI was associated with chest-specific body image, satisfaction, complications within 30 days or revisions in GM. RESULTS: Two hundred twenty-seven individuals meeting eligibility criteria were contacted to participate and one hundred thirty-seven responded (60.4% response rate). The mean age was 29.1 (SD=9.0) and mean BMI was 30.9 (SD=8.0), with 26.4% (N=60) of the cohort having a BMI>35. Chest-specific body image, and satisfaction with decision did not vary by BMI or breast resection weight. Complications and revisions were not associated with BMI. CONCLUSION: Individuals undergoing GM reported high rates of satisfaction following GM regardless of BMI. Complication and revision rates did not vary significantly by BMI or breast resection weight. Surgeons should re-evaluate the role BMI plays in patient selection and counseling for GM.

3.
JAMA Surg ; 158(10): 1070-1077, 2023 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-37556147

RESUMO

Importance: There has been increasing legislative interest in regulating gender-affirming surgery, in part due to the concern about decisional regret. The regret rate following gender-affirming surgery is thought to be approximately 1%; however, previous studies relied heavily on ad hoc instruments. Objective: To evaluate long-term decisional regret and satisfaction with decision using validated instruments following gender-affirming mastectomy. Design, Setting, and Participants: For this cross-sectional study, a survey of patient-reported outcomes was sent between February 1 and July 31, 2022, to patients who had undergone gender-affirming mastectomy at a US tertiary referral center between January 1, 1990, and February 29, 2020. Exposure: Decisional regret and satisfaction with decision to undergo gender-affirming mastectomy. Main Outcomes and Measures: Long-term patient-reported outcomes, including the Holmes-Rovner Satisfaction With Decision scale, the Decision Regret Scale, and demographic characteristics, were collected. Additional information was collected via medical record review. Descriptive statistics and univariable analysis using Fisher exact and Wilcoxon rank sum tests were performed to compare responders and nonresponders. Results: A total of 235 patients were deemed eligible for the study, and 139 responded (59.1% response rate). Median age at the time of surgery was 27.1 (IQR, 23.0-33.4) years for responders and 26.4 (IQR, 23.1-32.7) years for nonresponders. Nonresponders (n = 96) had a longer postoperative follow-up period than responders (median follow-up, 4.6 [IQR, 3.1-8.6] vs 3.6 [IQR, 2.7-5.3] years, respectively; P = .002). Nonresponders vs responders also had lower rates of depression (42 [44%] vs 94 [68%]; P < .001) and anxiety (42 [44%] vs 97 [70%]; P < .001). No responders or nonresponders requested or underwent a reversal procedure. The median Satisfaction With Decision Scale score was 5.0 (IQR, 5.0-5.0) on a 5-point scale, with higher scores noting higher satisfaction. The median Decision Regret Scale score was 0.0 (IQR, 0.0-0.0) on a 100-point scale, with lower scores noting lower levels of regret. A univariable regression analysis could not be performed to identify characteristics associated with low satisfaction with decision or high decisional regret due to the lack of variation in these responses. Conclusions and Relevance: In this cross-sectional survey study, the results of validated survey instruments indicated low rates of decisional regret and high levels of satisfaction with decision following gender-affirming mastectomy. The lack of dissatisfaction and regret impeded the ability to perform a more complex statistical analysis, highlighting the need for condition-specific instruments to assess decisional regret and satisfaction with decision following gender-affirming surgery.


Assuntos
Neoplasias da Mama , Mastectomia , Humanos , Feminino , Estudos Transversais , Tomada de Decisões , Neoplasias da Mama/cirurgia , Satisfação do Paciente , Emoções
4.
Actual. SIDA. infectol ; 31(111): 10-16, 20230000. graf, tab
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-1427156

RESUMO

Antecedentes: Se ha demostrado que la coinfección tu-berculosis y COVID-19 presenta peor evolución clínica. La inmunidad protectora se debilita frente a esta situación, generando fallo en el control de ambas infecciones, reac-tivación de formas latentes de tuberculosis y progresión exacerbada de los casos activos. Asimismo, la terapia con corticoides utilizada dentro del tratamiento de infecciones graves por COVID-19 puede generar inmunosupresión y precipitar la progresión de la tuberculosis.Objetivos: Describir las características clínicas, presenta-ción y evolución de los pacientes críticos con coinfección COVID-19 y tuberculosis. Evaluar la incidencia y letalidad de la asociación COVID-19 y tuberculosis en cuidados in-tensivos. Materiales y métodos: Se realizó un estudio retrospectivo, descriptivo. Se revisaron 12 historias clínicas de pacientes con coinfección COVID-19-tuberculosis sobre 1014 histo-rias clínicas de pacientes ingresados con diagnóstico de COVID-19, durante el periodo comprendido enero 2020 y junio 2022. Se utilizó estadística descriptiva. Resultados y discusión: Sobre un total de 1014 historias clínicas, se encontraron 12 pacientes con coinfección (in-cidencia de 0,011). La letalidad global en cuidados inten-sivos fue del 75%, a los 45 días fue del 83,3%, duplicando la letalidad general de los pacientes COVID-19 no coinfec-tados ingresados durante el mismo periodo (75% versus 37%). Los pacientes que requirieron ingreso a ventilación RESUMENARTÍCULO ORIGINALmecánica tuvieron una letalidad del 100% y aquellos que tenían infección por virus de inmunodeficiencia adquirida presentaron una letalidad de 100%. Resulta importante describir los hallazgos y alertar sobre la evolución desfavorable de aquellos pacientes que pre-sentan esta asociación a fin de optimizar el manejo y espe-cialmente recomendar la búsqueda de coinfección cuando el criterio clínico lo requiera


Background: Coinfection with tuberculosis and COVID-19 has been shown to have a worse clinical course. Protective immunity is weakened in this situation, leading to failure to control both infections, reactivation of latent forms of TB and exacerbated progression of active cases. Furthermore, corticosteroid therapy used in the treatment of severe COVID-19 infections can lead to immunosuppression and precipitate TB progression.Objectives: To describe the clinical characteristics, presentation and evolution of critically ill patients with COVID-19 and tuberculosis co-infection.To evaluate the incidence and lethality of COVID-19 and tuberculosis association in intensive care.Materials and methods: A retrospective, descriptive study was conducted. Twelve medical records of patients aged 18 years or older admitted to intensive care with a diagnosis of COVID-19 during the period January 2020 to July 2022 were reviewed. Descriptive statistics were used.Results and discussion: Out of a total of 1014 medical records, 12 patients were found with co-infection (incidence 0.011). The global intensive care case fatality was 75%, at 45 days it was 83.3%. This was twice the overall case fatality of non-co-infected COVID-19 patients admitted during the same period (75% versus 37%). Patients requiring admission to mechanical ventilation had a 100% case fatality and those with acquired immunodeficiency virus infection had a 100% case fatality.It is important to describe the findings and to alert to the worse evolution of those patients presenting with this association, in order to improve management and recommend searching for co-infection when clinical criteria require it


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Tuberculose/terapia , Cuidados Críticos , Coinfecção/imunologia , COVID-19/imunologia
5.
Oral Health Prev Dent ; 20(1): 321-330, 2022 Jun 28.
Artigo em Inglês | MEDLINE | ID: mdl-35866678

RESUMO

PURPOSE: To present updated information on odontogenic keratocyst (OKC) classification, etiology, genetic and molecular alterations, epidemiology, clinical presentation, radiographic characteristics, histological and immune histochemical features, differential diagnosis, treatment, and controversies, as well as a literature review of case frequencies in different countries. MATERIALS AND METHODS: Studies were selected using the key words 'odontogenic keratocyst,' 'odontogenic cysts,' 'odontogenic keratocyst and clinical study'. Full-text papers were reviewed on the basis of the inclusion and exclusion criteria. The literature search aimed to find articles that would show the frequency of OKC, dentigerous cyst, radicular cyst, and other cysts. RESULTS: OKC presents local aggression and high recurrence; therefore, a better understanding of its clinical characteristics and the genetic and molecular factors involved in this peculiar and controversial lesion is required. It is always essential to discuss treatment alternatives. Although OKC is an entity with a high recurrence, aggressive treatment is not advisable in all cases because factors such as commitment to anatomical structures and possible complications should be considered. However, periodic radiographic controls are advised. CONCLUSION: To reduce the high number of present cases worldwide, it is important to improve knowledge on this pathology so that accurate diagnoses can be achieved and appropriate treatment can be provided. OKC presents local aggression and high recurrence; therefore, a better understanding is needed of the clinical characteristics and genetic and molecular factors involved in OKC. Furthermore, it is always essential to discuss treatment alternatives.


Assuntos
Cistos Odontogênicos , Humanos , Cistos Odontogênicos/diagnóstico por imagem , Cistos Odontogênicos/epidemiologia , Cistos Odontogênicos/patologia
6.
Arthritis Care Res (Hoboken) ; 73(8): 1088-1105, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34235880

RESUMO

OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. CONCLUSION: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.


Assuntos
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico , Anticorpos Anticitoplasma de Neutrófilos/sangue , Imunossupressores/uso terapêutico , Reumatologia/normas , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/imunologia , Biomarcadores/sangue , Tomada de Decisão Clínica , Consenso , Técnicas de Apoio para a Decisão , Medicina Baseada em Evidências/normas , Humanos , Imunossupressores/efeitos adversos , Índice de Gravidade de Doença , Resultado do Tratamento
7.
Arthritis Rheumatol ; 73(8): 1384-1393, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34235883

RESUMO

OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). METHODS: Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long-term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. CONCLUSION: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.


Assuntos
Antirreumáticos/uso terapêutico , Medicina Baseada em Evidências/normas , Poliarterite Nodosa , Reumatologia/normas , Ciclofosfamida/uso terapêutico , Gerenciamento Clínico , Glucocorticoides/uso terapêutico , Humanos , Poliarterite Nodosa/diagnóstico , Poliarterite Nodosa/diagnóstico por imagem , Poliarterite Nodosa/tratamento farmacológico , Estados Unidos
8.
Arthritis Care Res (Hoboken) ; 73(8): 1061-1070, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34235889

RESUMO

OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). METHODS: Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long-term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. CONCLUSION: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.


Assuntos
Ciclofosfamida/uso terapêutico , Glucocorticoides/uso terapêutico , Imunossupressores/uso terapêutico , Poliarterite Nodosa/tratamento farmacológico , Reumatologia/normas , Tomada de Decisão Clínica , Consenso , Ciclofosfamida/efeitos adversos , Técnicas de Apoio para a Decisão , Quimioterapia Combinada , Medicina Baseada em Evidências/normas , Glucocorticoides/efeitos adversos , Humanos , Imunossupressores/efeitos adversos , Poliarterite Nodosa/diagnóstico , Poliarterite Nodosa/imunologia , Índice de Gravidade de Doença , Resultado do Tratamento
9.
Arthritis Rheumatol ; 73(8): 1366-1383, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34235894

RESUMO

OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. RESULTS: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations. CONCLUSION: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.


Assuntos
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos , Antirreumáticos/uso terapêutico , Medicina Baseada em Evidências/normas , Reumatologia/normas , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/diagnóstico , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/tratamento farmacológico , Anticorpos Monoclonais Humanizados/uso terapêutico , Síndrome de Churg-Strauss/diagnóstico , Síndrome de Churg-Strauss/tratamento farmacológico , Gerenciamento Clínico , Granulomatose com Poliangiite/diagnóstico , Granulomatose com Poliangiite/tratamento farmacológico , Humanos , Poliangiite Microscópica/diagnóstico , Poliangiite Microscópica/tratamento farmacológico , Indução de Remissão , Rituximab/uso terapêutico , Estados Unidos
10.
Rev. enferm. neurol ; 18(3): 115-123, 20191231.
Artigo em Espanhol | LILACS, BDENF | ID: biblio-1117853

RESUMO

Introducción: la cultura de seguridad del paciente permite trabajar de manera multidisc-plinaria, identificar vulnerabilidades y modificar áreas de oportunidad para disminuir riesgos que pudieran propiciar un error que cause daño al paciente. Objetivo: describir el grado de cultura de seguridad del paciente en un hospital de alta especialidad. Material y métodos: estudio cuantitativo, descriptivo y transversal, con técnica de mues-treo aleatorio simple. Se aplicó el cuestionario Hospital Survey on Patient Safety Culture, de la Agency for Healthcare Research and Quality. Bajo las pautas SQUIRE para mejorar la atención médica. Resultados: el porcentaje general del grado de cultura de seguridad del paciente fue 45.1%, la percepción del personal sobre el grado de seguridad global del paciente 8.1/10. La fortaleza principal: trabajo en equipo con 75.3%. Variables críticas: personal, dotación, sufi-ciencia y gestión (28.8%), problemas en cambios de turno (34.8%) y respuesta no punitiva a errores (21.5%). Conclusión: toda institución debe identificar las fortalezas y áreas de oportunidad, con el objetivo de vigilar los procesos que conllevan a mejorar la seguridad en atención y disminuir los sesgos que propician el error.


Assuntos
Humanos , Qualidade da Assistência à Saúde , Segurança , Cultura , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Segurança do Paciente
11.
Nutr Hosp ; 36(6): 1403-1417, 2019 Dec 26.
Artigo em Inglês | MEDLINE | ID: mdl-31657606

RESUMO

INTRODUCTION: Telomere length (TL) is a predictive biomarker of premature aging. Telomere shortening has been linked to age-related diseases and noncommunicable diseases (NCD), and may reflect the effects of behavioral, psychosocial and environmental factors on health status. Telomere attrition can be affected by lifestyle factors such as diet and physical activity. The search of studies included in this review was conducted on PubMed Central database. A majority of studies are cross-sectional, as there is a clear lack of prospective studies to evaluate the individual effect of dietary components, dietary patterns, and physical activity on TL in the long term. The current literature suggests that high adherence to Mediterranean diet (MD), with consumption of antioxidants, fiber and vegetables, as well as seeds and walnuts, is associated with longer TL. The dietary components of a healthy diet, such as carotenoids, vitamins A, C, D, E, polyphenols, fiber, and omega-3 fatty acids could help maintain TL. In contrast, a high consumption of sugary beverages, processed meat, and proinflammatory diets is associated with telomere shortening. In a majority of studies TL is positively associated with moderate physical activity. The predominant mechanisms through which a healthy diet and moderate physical exercise could mitigate telomere attrition include decreasing oxidative stress and inflammation. We shall not discuss the associations of possible risk or protective factors in terms of causality since the majority of studies are cross-sectional and randomized controlled trials are limited; accordingly, some results are inconclusive. For future research, we suggest evaluating the individual effects of dietary components, dietary patterns and physical activity, considering repeated measurements and exercise intensity, on TL. It is also advisable to include biomarkers of oxidative stress and inflammation proteins, and to measure telomerase activity.


INTRODUCCIÓN: La longitud de los telómeros (TL) es un biomarcador predictivo del envejecimiento prematuro. El acortamiento de los telómeros se ha relacionado con las enfermedades asociadas a la edad y las enfermedades no transmisibles (ENT), y puede reflejar los efectos de los factores conductuales, psicosociales y ambientales en el estado de salud. El desgaste de los telómeros puede verse afectado por factores del estilo de vida, como la dieta y la actividad física. La búsqueda de los estudios incluidos en esta revisión se realizó en la base de datos PubMed Central. La mayoría de los estudios son transversales, por lo que está clara la falta de estudios prospectivos que evalúen el efecto individual de los componentes dietéticos, los patrones dietéticos y la actividad física sobre el TL a largo plazo. Los componentes dietéticos de una dieta saludable, como los carotenoides, las vitaminas A, C, D, E, los polifenoles, la fibra y los ácidos grasos omega-3, podrían ayudar a mantener la TL. En contraste, el alto consumo de bebidas azucaradas, carne procesada y dietas proinflamatorias se asocia al acortamiento de los telómeros. En la mayoría de los estudios, el TL se asocia positivamente con la actividad física moderada. Los mecanismos predominantes que podrían mitigar el desgaste de los telómeros son la disminución del estrés oxidativo y la inflamación. No se discute la asociación de posibles factores de riesgo o de protección en términos de causalidad, ya que la mayoría de los estudios son transversales y los ensayos controlados aleatorios son limitados; por consiguiente, algunos resultados no son concluyentes. Para investigaciones futuras se sugiere evaluar los efectos individuales de los componentes dietéticos, los patrones de actividad física y dietética. También es aconsejable incluir biomarcadores de estrés oxidativo y proteínas inflamatorias, y medir la actividad de la telomerasa.


Assuntos
Dieta , Exercício Físico , Telômero/ultraestrutura , Pesquisa Biomédica/tendências , Ácidos Graxos Essenciais , Previsões , Humanos , Inflamação , Micronutrientes , Estresse Oxidativo
12.
Ann Rheum Dis ; 78(12): 1722-1731, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31562126

RESUMO

OBJECTIVE: To investigate the characteristics and risk factors of a novel parenchymal lung disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). METHODS: In a multicentre retrospective study, 61 cases were investigated using physician-reported clinical information and centralised analyses of radiological, pathological and genetic data. RESULTS: LD was associated with distinctive features, including acute erythematous clubbing and a high frequency of anaphylactic reactions to the interleukin (IL)-6 inhibitor, tocilizumab. Serum ferritin elevation and/or significant lymphopaenia preceded LD detection. The most prevalent chest CT pattern was septal thickening, involving the periphery of multiple lobes ± ground-glass opacities. The predominant pathology (23 of 36) was pulmonary alveolar proteinosis and/or endogenous lipoid pneumonia (PAP/ELP), with atypical features including regional involvement and concomitant vascular changes. Apparent severe delayed drug hypersensitivity occurred in some cases. The 5-year survival was 42%. Whole exome sequencing (20 of 61) did not identify a novel monogenic defect or likely causal PAP-related or macrophage activation syndrome (MAS)-related mutations. Trisomy 21 and young sJIA onset increased LD risk. Exposure to IL-1 and IL-6 inhibitors (46 of 61) was associated with multiple LD features. By several indicators, severity of sJIA was comparable in drug-exposed subjects and published sJIA cohorts. MAS at sJIA onset was increased in the drug-exposed, but was not associated with LD features. CONCLUSIONS: A rare, life-threatening lung disease in sJIA is defined by a constellation of unusual clinical characteristics. The pathology, a PAP/ELP variant, suggests macrophage dysfunction. Inhibitor exposure may promote LD, independent of sJIA severity, in a small subset of treated patients. Treatment/prevention strategies are needed.


Assuntos
Artrite Juvenil/complicações , Pneumopatias/epidemiologia , Pulmão/diagnóstico por imagem , Biópsia , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Incidência , Lactente , Pneumopatias/diagnóstico , Pneumopatias/etiologia , Masculino , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida/tendências , Tomografia Computadorizada por Raios X , Estados Unidos/epidemiologia
13.
Oncol Lett ; 17(6): 4779-4786, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31186683

RESUMO

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is expressed in most human cell types (example: Epithelial cells, fibroblasts and endothelial), it serves a key role in the control of cell survival, proliferation and motility. The abnormal expression of FAK has been associated with poor prognosis in cancer, including ovarian cancer. However, although FAK isoforms with specific molecular and functional properties have been characterized, there are a limited number of published studies that examine FAK isoforms in ovarian cancer. The aim of the present study was to analyze the expression level of FAK and its isoforms in ovarian cancer. The expression of FAK kinase and focal adhesion targeting (FAT) domains was determined with immunohistochemistry in healthy ovary, and serous and mucinous cystadenoma, borderline tumor and carcinoma samples. Additionally, the expression of FAK and its isoforms were investigated in three ovarian cancer-derived cell lines with western blotting and reverse transcription-semi-quantitative polymerase chain reaction. An increased expression of FAK kinase domain was determined in serous tumor samples and was associated with advancement of the lesion. FAK kinase domain expression was moderate-to-low in mucinous tumor samples. The expression of the FAK FAT domain in tumor samples was reduced, compared with healthy ovary samples; however, the FAT domain was localized to the cellular nucleus. Expression of alternative transcripts FAK°, FAK28,6 and FAK28 was determined in all three cell lines investigated. In conclusion, FAK kinase and FAT domains are differentially expressed among ovarian tumor types. These results indicated the presence of at least two isoforms of FAK (FAK and the putative FAK-related non-kinase) in tumor tissue, which is supported by the cells producing at least three FAK alternative transcripts. These results may support the use of FAK and its isoforms as biomarkers for ovarian cancer.

14.
Rev. argent. microbiol ; 50(2): 136-146, jun. 2018. ilus, tab
Artigo em Inglês | LILACS | ID: biblio-977230

RESUMO

The aim of the present study was to gather information regarding the molecular epidemiology of Human papillomavirus (HPV) and related risk factors in a group of women with low- and high-grade cervical lesions and cancer from the coastal region of Ecuador. In addition, we studied the evolution of HPV variants from the most prevalent types and provided a temporal framework for their emergence, which may help to trace the source of dissemination within the region. We analyzed 166 samples, including 57 CIN1, 95 CIN2/3 and 14 cancer cases. HPV detection and typing was done by PCR-sequencing (MY09/MY11). HPV variants and estimation of the time to most recent common ancestor (tMRCA) was assessed through phylogeny and coalescence analysis. HPV DNA was found in 54.4% of CIN1, 74.7% of CIN2/3 and 78.6% of cancer samples. HPV16 (38.9%) and HPV58 (19.5%) were the most prevalent types. Risk factors for the development of cervical lesions/cancer were the following: three or more pregnancies (OR = 4.3), HPV infection (OR = 3.7 for high-risk types; OR = 3.5 for HPV16), among others. With regard to HPV evolution, HPV16 isolates belonged to lineages A (69%) and D (31%) whereas HPV58 isolates belonged only to lineage A. The period of emergence of HPV16 was in association with human populations (tMRCA = 91 052 years for HPV16A and 27000 years for HPV16D), whereas HPV58A preceded Homo sapiens evolution (322 257 years). This study provides novel data on HPV epidemiology and evolution in Ecuador, which will be fundamental in the vaccine era.


El objetivo del presente estudio fue aportar información sobre la epidemiología molecular del virus del papiloma humano (human papillomavirus [HPV]) y los factores de riesgo asociados al desarrollo de lesiones cervicales y cáncer en mujeres de la costa del Ecuador. Además, se estudiaron la evolución de las variantes de los HPV más prevalentes y el marco temporal de su emergencia, para ayudar a rastrear la fuente de dispersión en la región. Se analizaron 166 muestras, incluyendo 57 y 95 casos de neoplasia intraepitelial cervical tipo 1 (CIN1) y tipo 2/3 (CIN2/3), respectivamente, y 14 de casos de cáncer. La detección/tipificación de HPV se realizó por PCR-secuenciación (MY09/MY11). La caracterización de variantes y la datación del ancestro común más reciente (tMRCA) se realizaron mediante filogenia y coalescencia. Se encontró ADN de HPV en el 54,4% de las muestras de CIN1, el 74,7% de las muestras de CIN2/3 y el 78,6% de las muestras de cáncer. Los tipos HPV16 (38,9%) y HPV58 (19,5%) fueron los más frecuentes. Los factores de riesgo para el desarrollo de lesiones cervicales/cáncer fueron 3 o más embarazos (OR = 4,3) e infección por HPV (O = 3,7 para HPV de alto riesgo, OR = 3,5 para HPV16), entre otros. En cuanto a la evolución viral, los aislados del HPV16 pertenecían a los linajes A (69%) y D (31%), mientras que los aislados del HPV58 pertenecían únicamente al linaje A. El período de emergencia del HPV16 estuvo asociado a poblaciones humanas (tMRCA = 91.052 años para HPV16Ay 27.000 para HPV16D), mientras que el del HPV58A precedió a la evolución de Homo sapiens (322.257 años). Este estudio proporciona datos novedosos sobre la epidemiología y la evolución del HPV en Ecuador, los cuales serán fundamentales en la era de la vacuna.


Assuntos
Feminino , Humanos , Filogenia , Neoplasias do Colo do Útero , Epidemiologia Molecular , Infecções por Papillomavirus , Papillomaviridae , DNA Viral/análise , Neoplasias do Colo do Útero/virologia , Infecções por Papillomavirus/genética , Infecções por Papillomavirus/epidemiologia , Equador/epidemiologia
15.
Rev Argent Microbiol ; 50(2): 136-146, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29157596

RESUMO

The aim of the present study was to gather information regarding the molecular epidemiology of Human papillomavirus (HPV) and related risk factors in a group of women with low- and high-grade cervical lesions and cancer from the coastal region of Ecuador. In addition, we studied the evolution of HPV variants from the most prevalent types and provided a temporal framework for their emergence, which may help to trace the source of dissemination within the region. We analyzed 166 samples, including 57 CIN1, 95 CIN2/3 and 14 cancer cases. HPV detection and typing was done by PCR-sequencing (MY09/MY11). HPV variants and estimation of the time to most recent common ancestor (tMRCA) was assessed through phylogeny and coalescence analysis. HPV DNA was found in 54.4% of CIN1, 74.7% of CIN2/3 and 78.6% of cancer samples. HPV16 (38.9%) and HPV58 (19.5%) were the most prevalent types. Risk factors for the development of cervical lesions/cancer were the following: three or more pregnancies (OR=4.3), HPV infection (OR=3.7 for high-risk types; OR=3.5 for HPV16), among others. With regard to HPV evolution, HPV16 isolates belonged to lineages A (69%) and D (31%) whereas HPV58 isolates belonged only to lineage A. The period of emergence of HPV16 was in association with human populations (tMRCA=91052 years for HPV16A and 27000 years for HPV16D), whereas HPV58A preceded Homo sapiens evolution (322257 years). This study provides novel data on HPV epidemiology and evolution in Ecuador, which will be fundamental in the vaccine era.


Assuntos
Epidemiologia Molecular , Infecções por Papillomavirus , Filogenia , Neoplasias do Colo do Útero , DNA Viral/análise , Equador/epidemiologia , Feminino , Humanos , Papillomaviridae , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/genética , Neoplasias do Colo do Útero/virologia
16.
PLoS One ; 12(4): e0175939, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28426725

RESUMO

The prolyl isomerase Pin1 plays a key role in the modulation of proline-directed phosphorylation signaling by inducing local conformational changes in phosphorylated protein substrates. Extensive studies showed different roles for Pin1 in physiological processes and pathological conditions such as cancer and neurodegenerative diseases. However, there are still several unanswered questions regarding its biological role. Notably, despite evidences from cultured cells showing that Pin1 expression and activity may be regulated by different mechanisms, little is known on their relevance in vivo. Using Danio rerio (zebrafish) as a vertebrate model organism we showed that pin1 expression is regulated during embryogenesis to achieve specific mRNA and protein distribution patterns. Moreover, we found different subcellular distribution in particular stages and cell types and we extended the study of Pin1 expression to the adult zebrafish brain. The analysis of Pin1 overexpression showed alterations on zebrafish development and the presence of p53-dependent apoptosis. Collectively, our results suggest that specific mechanisms are operated in different cell types to regulate Pin1 function.


Assuntos
Regulação da Expressão Gênica no Desenvolvimento , Regulação Enzimológica da Expressão Gênica , Peptidilprolil Isomerase de Interação com NIMA/metabolismo , Peixe-Zebra/embriologia , Animais , Peptidilprolil Isomerase de Interação com NIMA/genética , Especificidade por Substrato
17.
Pediatr Rheumatol Online J ; 14(1): 64, 2016 Nov 29.
Artigo em Inglês | MEDLINE | ID: mdl-27894310

RESUMO

BACKGROUND: Dystrophic calcifications may occur in patients with J uvenile Idiopathic Inflammatory Myopathy (JIIM) as well as other connective tissue and metabolic diseases, but a reliable method of measuring the volume of these calcifications has not been established. The purpose of this study is to determine the feasibility of low dose, limited slice, Computed Tomography (CT) to measure objectively in-situ calcification volumes in patients with JIIM over time. METHODS: Ten JIIM patients (eight JDM, two Overlap) with calcifications were prospectively recruited over a 2-year period to undergo two limited, low dose, four-slice CT scans. Calculation of the volume of calcifications used a CT post processing workstation. Additional patient data included: Disease Activity Scores (DAS), Childhood Myositis Assessment Scale (CMAS), myositis specific antibodies (MSA), and the TNFα-308 promoter region A/G polymorphism. Statistical analysis utilized the Pearson correlation coefficient, the paired t-test and descriptive statistics. RESULTS: Ten JIIM, mean age 14.54 ± 4.54 years, had a duration of untreated disease of 8.68 ± 5.65 months  MSA status: U1RNP (1), PM-Scl (1), Ro (1, 4 indeterminate), p155/140 (2), MJ (3), Mi-2 indeterminate (1), negative (3). 4/8 JDM (50%) were TNF-α-308 A+. Overall, the calcification volumes tended to decrease from the first to the second CT study by 0.5 cm3 (from 2.79 ± 1.98 cm3 to 2.29 ± 2.25 cm3). The average effective radiation dose was 0.007 ± 0.002, 0.010 ± 0.005, and 0.245 mSv for the upper extremity, lower extremity and chest, respectively (compared to a standard chest x-ray-- 0.02mSV effective dosage). CONCLUSION: We conclude: 1) the limited low dose CT technique provides objective data about volume of the calcifications in JIIM; 2) measuring the volume of calcifications in an extremity is associated with minimal radiation exposure; 3) This method may be useful to evaluate the efficacy of therapies for JIIM dystrophic calcification.


Assuntos
Calcinose/diagnóstico por imagem , Miosite/diagnóstico por imagem , Adolescente , Calcinose/patologia , Criança , Estudos de Viabilidade , Feminino , Humanos , Masculino , Miosite/patologia , Projetos Piloto , Doses de Radiação , Tomografia Computadorizada por Raios X/métodos , Adulto Jovem
18.
Biomed Res Int ; 2015: 194031, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26339592

RESUMO

Autoimmune diseases (AD) are classified into organ-specific, systemic, and mixed; all forms of AD share a high risk for cancer development. In AD a destructive immune response induced by autoreactive lymphocytes is started and continues with the production of autoantibodies against different targets; furthermore apoptosis failure and loss of balance in oxidative stress as a consequence of local or systemic inflammation are common features seen in AD as well. Micronucleus (MN) assay can be performed in order to evaluate loss of genetic material in a clear, accurate, fast, simple, and minimally invasive test. The MN formation in the cytoplasm of cells that have undergone proliferation is a consequence of DNA fragmentation during mitosis and the appearance of small additional nuclei during interphase. The MN test, widely accepted for in vitro and in vivo genotoxicity research, provides a sensitive marker of genomic damage associated to diverse conditions. In here, we present a review of our work and other published papers concerning genotoxic effect in AD, identified by means of the MN assay, with the aim of proposing this tool as a possible early biomarker for genotoxic damage, which is a consequence of disease progression. Additionally this biomarker could be used for follow-up, to asses genome damage associated to therapies.


Assuntos
Doenças Autoimunes/genética , Dano ao DNA/efeitos dos fármacos , Linfócitos/efeitos dos fármacos , Testes para Micronúcleos , Neoplasias/genética , Apoptose/efeitos dos fármacos , Doenças Autoimunes/imunologia , Doenças Autoimunes/patologia , Carcinógenos/toxicidade , Núcleo Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Fragmentação do DNA/efeitos dos fármacos , Mitose/efeitos dos fármacos , Mutagênicos/toxicidade , Neoplasias/induzido quimicamente , Neoplasias/patologia , Estresse Oxidativo/efeitos dos fármacos
19.
Aesthethika (Ciudad Autón. B. Aires) ; 11(2): 71-85, 20150900.
Artigo em Espanhol | LILACS | ID: lil-778775

RESUMO

La Historia de la Psicología constituye un campo privilegiado de reflexión sobre los procesos de construcción y transformación de los discursos y las prácticas de la Psicología a lo largo del tiempo, permitiendo situar en perspectiva la compleja diversidad disciplinar. La historia que recorre este artículo se propone describir, analizar y explicitar las condiciones que permitieron la emergencia de la Psicotecnia y sus primeras aplicaciones. Los orígenes de la Psicotecnia se ubican a comienzos del siglo XX y sus fundamentos teóricos se basaron en las derivaciones de la psicología experimental y en los aportes de la psicología de las diferencias individuales. Con herramientas derivadas de este entrecruzamiento, la psicología comenzaba a abordar demandas sociales y empresariales. La Primera Guerra Mundial marcó un momento de expansión y consolidación de la Psicotecnia. Cada uno de los países participantes en la guerra, convocaron a la Psicología para resolver cuestiones relacionadas con la selección, formación, rehabilitación, etc., de sus tropas. Tras la finalización de la Segunda Guerra Mundial, el término Psicotecnia, asociado a los países derrotados o debilitados por la guerra, se eclipsa y literalmente desaparece del concierto internacional. En su lugar se impone el término Psicología Aplicada que contaba tradicionalmente con el respaldo americano...


The History of Psychology is a privileged field of reflection on the processes of construction and transformation of the discourses and practices of psychology over time, allowing put into perspective the complex diversity of our discipline. The story that follows this article aims to describe, analyze and explain the conditions that allowed the emergence of Applied Psychology [Psicotecnia] and its first applications. The origins of the "Psicotecnia" are located at the beginning of the twentieth century and were based on referrals of experimental psychology and the contributions of the psychology of individual differences. With tools derived from this crossing, psychology began to address social and business demands. The First World War marked a period of expansion and consolidation of "Psicotecnia". Each of the countries participating in the war, called for psychology to resolve issues related to the selection, training and rehabilitation of their troops. After the end of the Second World War, the term "Psicotecnia" associated with the defeated or weakened countries during the war, literally disappears from the international arena. Instead, the term Applied Psychology ­that traditionally had US backing­ is imposed.


Assuntos
Humanos , Psicologia Aplicada/história , Psicologia Experimental/história , Psicologia/história , I Guerra Mundial
20.
Nutr Hosp ; 32(1): 291-8, 2015 Jul 01.
Artigo em Espanhol | MEDLINE | ID: mdl-26262729

RESUMO

Breast cancer (BC) is considered a global public health problem, and is the most frequently type diagnosed in Mexican women. Therefore, it is important to study the risk factors associated to this neoplasia in order to establish prevention strategies. The aim of this study was to evaluate the effect of hormonal contraceptives and hormone therapy (HT) use and period of use, breastfeeding practice, abdominal obesity and weight gain in adulthood, on the risk of BC in adult women from Northwest Mexico. This was a case-control study that included 162 women (81 cases and 81 controls). A sociodemographic and health questionnaire, and a survey history of body weight were applied to participants. Measurements of body weight, height and waist circumference were performed. To assess the association between BC risk and exposing factors, a multivariate logistic regression model was used. Average age of cases and controls were 51.8 ± 11.7 and 51.4 ± 11.3 years, respectively. No significant association was found between the use and period of use of hormonal contraceptives and HT with the risk of BC. The practice of breastfeeding (OR=0.34, 95%CI: 0.12- 0.92) and the time of exclusive breastfeeding (OR=0.64, 95%CI: 0.42-0.97; crude) were protective against the risk of BC. Abdominal obesity (OR=0.93, 95%CI: 0.90-0.97) and weight gain in early adulthood (OR=0.90, 95%CI: 0.85-0.95) were inversely associated to the risk of BC. In conclusion, the practice of breastfeeding may help prevent BC in Mexican women.


El cáncer de mama (CaMa) es considerado un problema de salud pública mundial, ocupando en México el primer lugar de incidencia en la mujer, por lo que es importante estudiar los factores de riesgo asociados para contribuir al establecimiento de estrategias de prevención. El objetivo del estudio fue evaluar el efecto del uso y el tiempo de utilización de anticonceptivos hormonales y terapia hormonal (TH), práctica de lactancia materna (LM), obesidad abdominal y el incremento de peso en la edad adulta sobre el riesgo de CaMa en mujeres adultas del noroeste de México. Fue un estudio de casos y controles que incluyó a 162 mujeres (81 casos y 81 controles). Las participantes respondieron un cuestionario sociodemográfico y de salud, una encuesta de historial de peso corporal y se realizaron mediciones de peso corporal, estatura y circunferencia de cintura. Se utilizó regresión logística multivariada para evaluar la asociación entre los factores de exposición y la neoplasia. La edad promedio de los casos fue de 51,8 ± 11,7 años y la de los controles de 51,4 ± 11,3 años. No se encontró asociación significativa del uso y tiempo de uso de anticonceptivos hormonales y de TH con la neoplasia. La práctica de LM (RM = 0,34, IC 95%: 0,12 - 0,92) y el tiempo de lactancia materna exclusiva (LME) (RM = 0,64, IC 95%: 0,42 - 0,97; cruda) resultaron factores protectores contra el CaMa. La obesidad abdominal (RM = 0,93, IC 95%: 0,90 - 0,97) y el incremento de peso (RM = 0,90, IC 95%: 0,85 - 0,95) tuvieron una asociación inversa con el riesgo de CaMa. Se concluye que la práctica de LM pudiera ayudar a la prevención del CaMa en mujeres mexicanas.


Assuntos
Aleitamento Materno , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/etiologia , Obesidade/complicações , Reprodução , Adulto , Estudos de Casos e Controles , Feminino , Humanos , México/epidemiologia , Pessoa de Meia-Idade , Razão de Chances , História Reprodutiva , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA